ResearcherJohns Hopkins UniversityNo recent work listed
Katherine Y. Fan
Known by name at one institution; no external author ID yet. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2013: 3 papers · 2014: 1 paper
Papers 4
- Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. Co-author DOI 10.6004/jnccn.2014.0006↗
- Management of pancreatic cancer. First author DOI 10.1016/j.currproblcancer.2013.10.001↗
- Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. First author DOI 10.1016/j.ijrobp.2013.03.032↗
- Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic… First author DOI 10.1016/j.ijrobp.2013.06.2039↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Aaron Tyler Wild · 4 shared papers, 2013–2014 · strength 0.15
- Paper Management of pancreatic cancer. DOI 10.1016/j.currproblcancer.2013.10.001↗
- Paper Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. DOI 10.6004/jnccn.2014.0006↗
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Joseph M. Herman · 4 shared papers, 2013–2014 · strength 0.15
- Paper Management of pancreatic cancer. DOI 10.1016/j.currproblcancer.2013.10.001↗
- Paper Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. DOI 10.6004/jnccn.2014.0006↗
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Christopher Lee Wolfgang · 3 shared papers, 2013–2014 · strength 0.09
- Paper Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. DOI 10.6004/jnccn.2014.0006↗
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Paper Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreati… DOI 10.1016/j.ijrobp.2013.03.032↗
- Timothy Michael Pawlik · 3 shared papers, 2013–2014 · strength 0.09
- Paper Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. DOI 10.6004/jnccn.2014.0006↗
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Paper Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreati… DOI 10.1016/j.ijrobp.2013.03.032↗
- Ralph H. Hruban · 3 shared papers, 2013–2014 · strength 0.09
- Paper Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. DOI 10.6004/jnccn.2014.0006↗
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Paper Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreati… DOI 10.1016/j.ijrobp.2013.03.032↗
- Daniel A. Laheru · 3 shared papers, 2013–2014 · strength 0.09
- Paper Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. DOI 10.6004/jnccn.2014.0006↗
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Paper Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreati… DOI 10.1016/j.ijrobp.2013.03.032↗
- Dung Thi Le · 2 shared papers, 2013–2014 · strength 0.06
- Ana De Jesus‐Acosta · 2 shared papers, 2013–2014 · strength 0.06
- Amy Hacker‐Prietz · 2 shared papers, 2013–2014 · strength 0.06
- Amanda L. Blackford · 2 shared papers, 2013 · strength 0.06
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Paper Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreati… DOI 10.1016/j.ijrobp.2013.03.032↗
- Barish H. Edil · 2 shared papers, 2013 · strength 0.06
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Paper Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreati… DOI 10.1016/j.ijrobp.2013.03.032↗
- Ross C. Donehower · 2 shared papers, 2013 · strength 0.06
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Paper Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreati… DOI 10.1016/j.ijrobp.2013.03.032↗
- Laura DeLong Wood · 2 shared papers, 2013 · strength 0.06
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Paper Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreati… DOI 10.1016/j.ijrobp.2013.03.032↗
- Manuel M. Hidalgo · 2 shared papers, 2013 · strength 0.06
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Paper Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreati… DOI 10.1016/j.ijrobp.2013.03.032↗
- Richard David Schulick · 2 shared papers, 2013 · strength 0.06
- Paper Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and che… DOI 10.1016/j.ijrobp.2013.06.2039↗
- Paper Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreati… DOI 10.1016/j.ijrobp.2013.03.032↗
- Phuoc Tho Tran · 1 shared paper, 2014 · strength 0.03
- Avani Satish Dholakia · 1 shared paper, 2014 · strength 0.03
- Charles Chia-chuen Hsu · 1 shared paper, 2014 · strength 0.03
- Rachit Kumar · 1 shared paper, 2014 · strength 0.03
- Elliot K. Fishman · 1 shared paper, 2014 · strength 0.03
- Luis Alberto Diaz · 1 shared paper, 2014 · strength 0.03
- Christine A. Iacobuzio–Donahue · 1 shared paper, 2013 · strength 0.03
- Susannah G. Ellsworth · 1 shared paper, 2013 · strength 0.03
- Lei Zheng · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.